Join
Live feed
·
INSIDERFilingvia Quantisnow
CytomX Therapeutics Inc. logo

General Counsel Rowland Lloyd A sold $6,112 worth of shares (10,203 units at $0.60), decreasing direct ownership by 8% to 120,594 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
CTMX· CytomX Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CTMX (CytomX Therapeutics Inc.) and more on Quantisnow.